Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

953 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ATLANTIC and beyond: an interview with Professor Azfar Zaman.
Zaman A, Wu W. Zaman A, et al. Future Cardiol. 2015;11(1):13-5. doi: 10.2217/fca.14.75. Future Cardiol. 2015. PMID: 25606697
Professor Azfar Zaman speaks to Wing Wu, Commissioning Editor: Professor Azfar Zaman is a Consultant Interventional Cardiologist at Freeman Hospital and Professor of Cardiology at Newcastle University. ...In 2012, he was appointed Specialty Group Lead for Car …
Professor Azfar Zaman speaks to Wing Wu, Commissioning Editor: Professor Azfar Zaman is a Consultant Interventional Car …
The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX.
Gao C, Kogame N, Modolo R, Takahashi K, Wang R, Kawashima H, Ono M, Hara H, Tomaniak M, Zaman A, de Winter RJ, van Geuns RJ, Kaul U, Serruys PW, Onuma Y. Gao C, et al. Among authors: zaman a. Future Cardiol. 2021 Mar;17(2):227-237. doi: 10.2217/fca-2019-0083. Epub 2020 Sep 10. Future Cardiol. 2021. PMID: 32907391 Review.
A prospective multicentre randomised all-comers trial to assess the safety and effectiveness of the thin-strut sirolimus-eluting coronary stent SUPRAFLEX: rationale and design of the Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) trial.
Modolo R, Chichareon P, Kogame N, Asano T, Chang CC, de Winter RJ, Kaul U, Zaman A, Spitzer E, Takahashi K, Katagiri Y, Soliman OII, van Es GA, Morel MA, Onuma Y, Serruys PW. Modolo R, et al. Among authors: zaman a. EuroIntervention. 2019 Jul 20;15(4):e362-e369. doi: 10.4244/EIJ-D-18-00499. EuroIntervention. 2019. PMID: 30066672 Free article. Clinical Trial.
Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators. Zaman A, et al. Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28. Lancet. 2019. PMID: 30827782 Clinical Trial.
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial).
Chang CC, Spitzer E, Chichareon P, Takahashi K, Modolo R, Kogame N, Tomaniak M, Komiyama H, Yap SC, Hoole SP, Gori T, Zaman A, Frey B, Ferreira RC, Bertrand OF, Koh TH, Sousa A, Moschovitis A, van Geuns RJ, Steg PG, Hamm C, Jüni P, Vranckx P, Valgimigli M, Windecker S, Serruys PW, Soliman O, Onuma Y. Chang CC, et al. Among authors: zaman a. Am J Cardiol. 2019 Dec 15;124(12):1833-1840. doi: 10.1016/j.amjcard.2019.08.049. Epub 2019 Sep 26. Am J Cardiol. 2019. PMID: 31648781 Clinical Trial.
A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial.
Hara H, Gao C, Kogame N, Ono M, Kawashima H, Wang R, Morel MA, O'Leary N, Sharif F, Möllmann H, Reiber JHC, Sabaté M, Zaman A, Wijns W, Onuma Y, Serruys PW. Hara H, et al. Among authors: zaman a. EuroIntervention. 2020 Dec 18;16(12):e997-e1004. doi: 10.4244/EIJ-D-20-00772. EuroIntervention. 2020. PMID: 32928717 Free article. Clinical Trial.
Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin Strut Sirolimus-Eluting Coronary Stent Supraflex: Two-Year Outcomes of the TALENT Trial.
Gao C, Kogame N, Sharif F, Smits PC, Tonino P, Hofma S, Moreno R, Choudhury A, Petrov I, Cequier A, Colombo A, Kaul U, Zaman A, de Winter RJ, Onuma Y, Serruys PW. Gao C, et al. Among authors: zaman a. Circ Cardiovasc Interv. 2021 Mar;14(3):e010312. doi: 10.1161/CIRCINTERVENTIONS.120.010312. Epub 2021 Mar 9. Circ Cardiovasc Interv. 2021. PMID: 33685213 No abstract available.
Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial.
de Winter RJ, Zaman A, Hara H, Gao C, Ono M, Garg S, Smits PC, Tonino PAL, Hofma SH, Moreno R, Choudhury A, Petrov I, Cequier A, Colombo A, Kaul U, Onuma Y, Serruys PW. de Winter RJ, et al. Among authors: zaman a. EuroIntervention. 2022 Aug 19;18(6):492-502. doi: 10.4244/EIJ-D-21-00766. EuroIntervention. 2022. PMID: 35285804 Free PMC article. Clinical Trial.
Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial: Feasibility, Diagnostic Performance of Quantitative Flow Ratio, and Clinical Prognostic Value of Functional SYNTAX Score Derived From Quantitative Flow Ratio in Patients With 3-Vessel Disease.
Asano T, Katagiri Y, Chang CC, Kogame N, Chichareon P, Takahashi K, Modolo R, Tenekecioglu E, Collet C, Jonker H, Appleby C, Zaman A, van Mieghem N, Uren N, Zueco J, Piek JJ, Reiber JHC, Farooq V, Escaned J, Banning AP, Serruys PW, Onuma Y. Asano T, et al. Among authors: zaman a. JACC Cardiovasc Interv. 2019 Feb 11;12(3):259-270. doi: 10.1016/j.jcin.2018.09.023. JACC Cardiovasc Interv. 2019. PMID: 30409759 Free article.
Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.
Garg S, Chichareon P, Kogame N, Takahashi K, Modolo R, Chang CC, Tomaniak M, Fath-Ordoubadi F, Anderson R, Oldroyd KG, Stables RH, Kukreja N, Chowdhary S, Galasko G, Hoole S, Zaman A, Hamm CW, Steg PG, Jüni P, Valgimigli M, Windecker S, Onuma Y, Serruys PW. Garg S, et al. Among authors: zaman a. Catheter Cardiovasc Interv. 2020 Dec;96(7):1369-1378. doi: 10.1002/ccd.28649. Epub 2019 Dec 19. Catheter Cardiovasc Interv. 2020. PMID: 31854112 Clinical Trial.
953 results